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Abstract 26 
Coronary Heart Disease (CHD) is the leading cause of death globally. The placement of drug-eluting 27 
stents (DESs) in diseased coronary arteries is the most successful minimally-invasive intervention to 28 
treat CHD. The key limitations of such interventional therapy are the risk of in-stent restenosis (ISR) 29 
and late stent thrombosis. This paper investigates a new drug-release system by formatting 30 
nanoparticles as drug carriers, which are later subjected to an external ultrasonic stimulus for 31 
controlled drug release remotely for DESs. The drug delivery could delay smooth muscle cell growth 32 
whilst enabling effective regeneration of a functional endothelium. Microcapsules were produced by 33 
employing a layer-by-layer technique, encapsulated with Rhodamine 6G dye used in place of anti-34 
restenotic drugs. Gold nanoparticles were employed as a shell in the microcapsules. The presence of 35 
gold nanoparticles significantly enhanced the efficiency of the ultrasonically induced dye release from 36 
the microcapsules and increased the sensitivity of the microcapsules to ultrasonic stimulation 37 
compared to those without gold nanoparticles. 38 
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1. Introduction 49 
Coronary Heart Disease (CHD) is a global health challenge, resulting in around 17.3 million deaths 50 
annually [1]. The placement of stents in diseased coronary arteries is the most successful minimally-51 
invasive intervention to treat CHD. The most advanced stents are drug-eluting stents (DES), which 52 
release a drug to inhibit the excessive smooth muscle proliferative process responsible for the 53 
inconsistent results achieved with bare metal stents.  However, there is evidence that DES prevent 54 
regrowth of the endothelial cell layer (endothelium) that lines the innermost layer of the artery and it is 55 
increasingly clear that regeneration of this layer is crucial to securing positive long term outcomes [2].   56 
There is thus a need for a stent that inhibits smooth muscle cell growth whilst enabling effective 57 
regeneration of a functional endothelium. Current DES drug release profiles lead to high initial anti-58 
proliferative drug concentrations within the artery wall, which slowly decay over weeks and months [3].  59 
However, the process of endothelial regeneration is thought to occur within the first few days following 60 
bare metal stent implantation [4], whilst the excessive smooth muscle cell proliferation response is 61 
significantly delayed and occurs over weeks and months [5].  In this context, it is perhaps not surprising 62 
that existing DES have been associated with incomplete regeneration of the endothelium.  Any drug 63 
delivery which could delay drug release until after the endothelium had fully healed would therefore be a 64 
significant advance.  The aim of the research is to investigate ultrasound activated nanoparticles as a 65 
means of achieving this, with drug being released into the artery wall when it is most needed. 66 
 67 
However, in-stent restenosis (ISR) remains a serious problem following implantation. The major reason 68 
for ISR is the injured arterial wall causing smooth muscle cell (SMC) proliferation and scar tissue 69 
accumulation [6]. Meanwhile, drug release happens spontaneously after implantation and often is 70 
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uncontrolled [7]. To cope with this problem, nanocapsules combined with a drug delivery system can 71 
enable drug release in a specific site, as requirements [8-10].  72 
 73 
Stimuli-responsive nanocapsules can release the drug in a controlled manner and the non-invasive nature 74 
of the technique has advantages in therapeutic application, such as reduced possibility of infection, 75 
avoided damage to surrounding tissues by devices. Most of the literature on nanoparticulate carrier 76 
systems is based on the employment of lipid, polymeric, different types of nanoparticulate carriers, and 77 
self-assembling carriers [10]. In general, the layer-by-layer assembly of nanocapsules shows advantages: 78 
it achieves the integration of component materials from different nature within the films, and it makes the 79 
incorporation of various biomolecules into the films. The layer-by-layer technique consists of 80 
renaturation of polyion adsorption, allowing the alternation of the terminal charge after each subsequent 81 
layer deposition. Furthermore, it achieves a defined control over the thickness, structure, mechanical 82 
characteristics and composition of assembled materials [11]. 83 
 84 
Gold nanoparticles (AuNP) have been studied for many years in applications such as cancer treatment 85 
[12]. They have high biocompatibility, ease of surface modification, facile synthesis, and tuneable optical 86 
characteristics [13]. Based on previous research, the release efficiency was investigated by coating gold 87 
nanoparticles in the microcapsules shell [14]. When subjected to ultrasound, the microcapsule wall 88 
undergoes a morphological change due to shear forces due to the ultrasonic oscillations. If the ultrasonic 89 
ZDYHOHQJWKFRUUHODWHVWRWKHPLFURFDSVXOH¶VVL]HLWFDQPD[LPLVHWKHHIIHFW$W0+]WKHZDYHOHQJWK90 
closes to the size of PE microcapsules [15]. With the introduction of a rigid material such as the AuNP, 91 
WKH KLJKHU DPRXQW RI WKH HPEHGGHG QDQRSDUWLFOHV OHDGV WR D GHFUHDVHG <RXQJ¶V PRGXOXV DQG92 
microcapsule shell elasticity [16]. This can influence the fracture rate under ultrasonic triggering, making 93 
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them more vulnerable to ultrasound.  In addition, the gold nanoparticles are inert and are non-toxic, so 94 
they are a feasible material for medical applications. Moreover, the mechanical properties of gold 95 
nanoparticles also perform well making the microcapsules relative stable [17, 18]. 96 
 97 
Ultrasound is an effective external stimulation that can induce encapsulated drug delivery in vivo [19]. 98 
Therefore, ultrasound can act upon biomolecules. Ultrasound-responsive polymers for drug delivery 99 
systems have been studied in medical diagnostics and treatment [20]. Some polymeric systems that 100 
respond to ultrasound are mainly polymeric micelles, gels or other layer-by-layer (LbL) coated 101 
nanoparticles. Langer et al., have studied the release rate of incorporated components through the 102 
stimulation of ultrasound from polymers, including polylactides, biodegradable polyglycolides and 103 
ethylene-vinyl acetate copolymers [21-27]. It has been shown that ultrasonic stimulation can facilitate the 104 
permeation through some polymers with no erosion and enhance the decomposition rate in some 105 
biodegradable polymers [28][29]. Miyazaki et al. studied the ethylene-vinyl alcohol (EVAL) copolymer 106 
and insulin in diabetic rats and were able to control insulin release through the ultrasonic stimulation 107 
[30]. Receiving implants encapsulating insulin produced an ultrasonic stimulation (1MHz, 1 W/cm2) and 108 
a significant decrease in the level of blood glucose was observed. The results demonstrated a rapid rate of 109 
release of insulin in the targeted region. In previous research of this group, they also demonstrated that 110 
the release rate of 5-fluorouracil from an EVAL copolymer can rise at desired times upon the ultrasonic 111 
stimulation in vivo [31]. Ultrasonic stimulation can induce the collapse of drug carriers and achieve 112 
payload release for the uptake of target cells. The site specificity can be promoted by incorporating a 113 
surface ligand on the carrier, which is able to bind to specific receptors for specific targeting [32][33]. 114 
 115 
 116 
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2. Methods 117 
2.1.Synthesis of polylactic acid (PLA) microcapsules 118 
The work in this research is an attempt to develop a smart drug nanostructured delivery system that is 119 
controllable using ultrasonic stimulation.  This research focused on the polyelectrolytes like Polylactic 120 
acid (PLA), Poly(allylamine hydrochloride) (PAH), and Poly(styrene sulfonate) (PSS) because of their 121 
feasibility and their ability to function as a drug carrier. Rhodamine 6G, a kind of fluorescein dye, loaded 122 
in microcapsules was used as a drug surrogate in this model system for the controlled release studies. 123 
 124 
The core of the microcapsule was  made up of PLA microparticles. PLA microcapsules were achieved by 125 
using the nanoprecipitation method and this method has been introduced in previous research [34]. The 126 
main procedure to generate PLA/Rhodamine 6G microcapsules was to dissolve PLA in acetone and 127 
equilibrate for 12 hours at room temperature. Next, Rhodamine 6G was added to the acetone solution. 128 
Gradually, the colour changes of an acetone solution were observed from colourless to bright red due to 129 
the Rhodamine 6G becoming dissolved. The organic solution was stirred to allow the PLA and the 130 
Rhodamine 6G to become completely attached. After stirring, the organic solution was added drop by 131 
drop into distilled water containing no surfactant, with appropriate stirring for 2 hours. After injecting the 132 
organic phase into the aqueous phase, a conspecific microdispersion was obtained. The PLA 133 
microcapsules were suspended in water through centrifugation. The PLA/Rhodamine 6G capsules served 134 
as the cores of the microcapsules for the next layer-by-layer assemblies. The Rhodamine 6G dye served 135 
as a tracer material in place of anti-restenotic drugs. It can be easily detected using fluorescence 136 
spectroscopy. 137 
 138 
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The layers coated on the PLA cores contain PAH polymers (positive charged), PSS polymer (negative 139 
charged) and citrate stabilized gold nanoparticles (negative charged). With the opposite charge on 140 
polyelectrolytes, the microcapsules can  be formed and the number of layers can  be varied as required. 141 
Zeta potential measurement was employed to assess the layer-by-layer assembly process. In terms of the 142 
remote ultrasonic stimulation process, the microcapsules suspended in liquid can be stimulated. In the 143 
further clinical application, the system aims to allow the drug release from DES to occur in a controllable 144 
manner.  145 
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Figure 1 The layering processes of microocapsules.  147 
 148 
The grey sphere represents the PLA microo-cores; the pink dots represent the Rhodamine 6G which 149 
serves as a tracer material in place of anti-restenotic drugs; the green layer represents the PAH layer 150 
which is positive charged; the blue layer represents the PSS layer which is negative charged; the gold 151 
layer represents the gold nanoparticles which are negative charged. PLA microcapsules consist of a PLA 152 
core, PAH, PSS and gold nanoparticles shells fabricated by a layer-by-layer assembly technique. In brief, 153 
a 37.5 mL of PAH (1 mg/ml) aqueous solution was added to 25 mL of the PLA and stirred for 2 hours. 154 
The solution was centrifuged for 15 minutes at 13000 rpm and the supernatant was removed. The PAH 155 
coated microcapsules were resuspended in 31 mL of distilled water for the next layer assembly. For the 156 
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second polyelectrolyte layer coating, 46.5 ml of PSS (1 mg/ml) was added to the above solution and 157 
stirred for 2 hours. After centrifuging employing the same parameters, PAH/PSS coated microcapsules 158 
were re-suspended in 38 ml of distilled water. The third layer of PAH was assembled following the same 159 
process and the PLA-Rh6G/PAH/PSS/PAH microcapsules were again redispersed in 47 ml of water. 160 
Next 28.2 mL of citrate stabilized gold nanoparticles (25 mM, synthesized by the sodium citrate 161 
reduction method [35]), was added and was vigorously stirred for 2 hours. Following centrifugation and 162 
re-suspension, the last layer of PAH was assembled in the same way. Finally PLA-Rh6G 163 
/PAH/PSS/AuNP/PAH core-shell structure composite microcapsules were obtained after centrifugation 164 
and re-suspension, ready for the ultrasonic stimulation experiments. 165 
 166 
2.2. Ultrasonic stimulation 167 
In this research, the trigger mechanism was remotely stimulated with ultrasound at a frequency of 1MHz, 168 
which poses no harm for the human body within a safe range of frequency.  In this research, a hand-held 169 
ultrasound device with a frequency of 1 MHz was employed for the stimulation of PLA-Rh 170 
6G/PAH/PSS/PAH/AuNP/PAH microcapsules. The technology of therapeutic ultrasound is a high 171 
frequency sound vibration which cannot be felt by humans, and can stimulate tissue up to 5 cm beneath 172 
thH VNLQ¶V VXUIDFH The transducer used in the experiment is a therapeutic ultrasound device 173 
ULTRALIEVE made by Actegy Ltd UK. The effective intensity that represents the amount of energy 174 
transferred to the tissues is 2.4W/cm2. Power supply input is at AC 100-240V 50/60Hz, 0.35A.The size 175 
of the transducer is 34mm diameter × 10mm high and the effective radiating area is 4cm2. 176 
 177 
It is generally tissues or microcapsules which contain components that are sensitive to the effects of heat. 178 
Abnormalities in biochemical processes may appear following the increase of temperature above the 179 
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normal basal levels. Normally, the heat generated by ultrasound is mostly absorbed by blood circulation 180 
in vivo, and some heat is distributed through adjacent tissues. Therefore, the heat imparted onto body 181 
tissue should be given further attention, otherwise, some tissues or cells will be destroyed . The ultrasonic 182 
stimulation process in this project was not active for a long period of time to avoid overheating the 183 
microcapsules. In this project, the frequency of medical device was 1MHz, which meets the safety 184 
requirement in human body application. 185 
 186 
The duty cycle contains three different levels including Low (30% duty cycle, 0.75W/cm2), Medium 187 
(40% duty cycle, 1.0W/cm2) and High (50% duty cycle, 1.2W/cm2). The duty cycle is defined as the 188 
percentage during one period in which the signal is active [36-37]. A schematic diagram of the ultrasonic 189 
stimulation imparted onto the microcapsules is shown in Figure 2. 190 
 191 
 D=T/P×100%                                                                      (1) 192 
 193 
,Q (TXDWLRQ  ' UHSUHVHQWV GXW\ F\FOH 7ȝV UHSUHVHQWV WKH GXUDWLRQ RI DFWLYH VLJQDO DQG 3ȝV194 
represents total duration of signal. For example, a 30% duty cycle pulsed waveform would have 195 
ultrasound on for a total of 30% of the entire treatment, and off for a total of 70%. A 100% duty cycle is 196 
WKHVDPHRI³FRQWLQXRXV´7KHGHYLFHXVHGLQWKLVUHVHDUFKWKHGXW\F\FOHLVIL[HGZKLFKLQFOXGHV197 
40% and 50%.  198 
 199 
 200 
 201 
 202 
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 207 
 208 
 209 
Figure 2 Schematic diagram of the ultrasonic stimulation imparted onto the microcapsules.  210 
 211 
The PLA-Rh6G/PAH/PSS/PAH/AuNP/PAH microcapsules were suspended in the tube and the tube was 212 
fixed in water. The ultrasound device was fixed and kept working, which is shown on the left of figure 2. 213 
In the microcapsules details shown on the right of figure 2, the gray spheres represent the PLA 214 
microcapsules, the red particles represent Rhodamine 6G dye, the blue curves represent the PAH layer 215 
(positive charged), the black curves represent the PSS layer (negative charged), and the yellow curves 216 
represent the AuNP shell. The dye is released by the stimulation of ultrasound. 217 
 218 
In the future, these drug-loaded microcapsules will be planned to apply to the stents, allowing for a 219 
stimuli-response to ultrasound. 220 
 221 
3 Results 222 
 223 
3.1 SEM analysis microcapsules 224 
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PLA-Rh6G /PAH /PSS /PAH /AuNP / PAH/ microcapsules were prepared by an alternating deposition 225 
of cationic polymers (PAH) and anionic polymers (PSS) onto the PLA cores doped with Rh6G. An SEM 226 
image of the microcapsules is shown in Figure 3. 227 
 228 
 229 
(a)                                                                                                (b)       230 
Figure 3. SEM image of PLA-Rh6G/PAH/PSS/PAH/AuNP/PAH microcapsules. (a) SEM image of 231 
PLA/Rh6G/PAH/PSS/PAH/AuNP/PAH microcapsules. (b) The size distribution of microcapsules. 232 
 233 
Figure 3 shows that the majority of the microcapsules have dispersed spherical shapes with an average 234 
size of 165 ± 25 nm ( 200 microcapsules were accounted). 235 
 236 
3.2 Characterisation of the microcapsule assemblies 237 
 238 
In this research, the microcapsules were synthesized with four polymer layers and one AuNP layer, 239 
which contained opposite charges, via layer-by-layer self-assembly processes. To examine the layer-by-240 
layer assembly of PAH, PSS and AuNP on the PLA microcapsules, the sequential assembly procedures 241 
were monitored by means of zeta potential of the microcapsules. The variation of zeta potential with the 242 
sequential adsorption of the polyelectrolyte layer for the PAH/PSS/PAH/AuNP/PAH coatings is shown 243 
in Figure 4. 244 
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 245 
 246 
 247 
 248 
Figure 4.  Zeta potential measurements in the layer-by-layer assembly of the micro-capsules. 249 
 250 
The zeta potential value of the pristine PLA microcapsules was negative (-34.5 mV). This is believed to 251 
be due to the carboxylic groups present at the surface of the PLA microcapsules [38]. It was observed 252 
from the zeta potential measurements that the adsorption of a positively charged PAH layer on the PLA-253 
Rh6G microcapsules changed the zeta potential from -34.5 mV to +30.4 mV. Subsequently, the 254 
deposition of a PSS layer led to another potential reversal from +30.4 to -50 mV. Further alternating 255 
deposition of the PAH, AuNP and PAH led to continuous reversals in zeta potentials. This revealed a 256 
stepwise layer assembly during the fabrication of the composite microcapsules. 257 
 258 
The UV-vis spectrum of the PLA-Rh 6G/PAH/PSS/PAH/AuNP microcapsules is  shown in Figure 5. An 259 
absorption band due to the surface plasmon resonance of gold nanoparticles was observed indicating the 260 
presence of gold nanoparticles in the microcapsules. A red-shift of the surface plasmon band from 519 261 
nm shown in Figure 5(b) to 556 nm in figure.5 (a) may possibly be due to the aggregation of the gold 262 
nanoparticles when they were assembled onto the microcapsules. This absorption overlaps with a slope 263 
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of scattering from the large microcapsules. The absorption of Rhodamine 6G (526 nm) is not visible here 264 
because it overlaps with the strong scattering of the micro-capsules and also the absorption band of the 265 
gold nanoparticles.  266 
 267 
                       268 
                         (a)                                                (b) 269 
                                                       270 
Figure 5.  (a) Extinction spectrum of the PLA/Rh6G/PAH/PSS/PAH/AuNP/PAH micro-capsules (556nm). (b) UV-vis 271 
extinction spectrum of colloidal gold nanoparticles (519nm). 272 
 273 
3.3 Ultrasonic stimulation of the microcapsules 274 
The release of Rhodamine 6G dye from the microcapsules after each ultrasonic stimulation was 275 
examined via the measurement of concentration of Rh6G in the supernatants. Both the samples and the 276 
control samples (microcapsules without gold nanoparticles) undergo ultrasonic stimulation at three 277 
different duty cycles. Figure 6 shows the fluorescence intensity change of the dye released from the PLA-278 
Rh6G/PAH/PSS/PAH/AuNP/PAH microcapsules against the ultrasonic stimulation times of the different 279 
duty cycles. The measurement was taken after each 15 minutes of stimulation. 280 
 281 
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 282 
Figure 6. Rhodamine 6G concentration released from the capsules with gold nanoparticles against the ultrasonic stimulation 283 
time of the different duty cycles. The orange line represents the total concentration of Rhodamine 6G contained in the 284 
capsules.  285 
 286 
The measurement was repeated twice independently in the collection of the presented in vitro data. The 287 
graph represents means with error bars for six times. Graph markers denote the data mean. The bars 288 
represent one standard deviation of the mean.  Rhodamine 6G concentration in Figure 6 showed that 289 
samples after high-duty cycle ultrasonic stimulation carried out 6 times, 15 minutes each time, released 290 
more of the dye than under medium or low-duty cycle treatment. Little dye was released from these 291 
microcapsules after the first 15 minutes of the stimulation. Clear increases of Rhodamine 6G were 292 
observed after the second stimulation, although no significant differences were found among the different 293 
duty cycles. With the increase of the ultrasonic stimulation times, the Rhodamine 6G concentration 294 
further increased. This indicates that the ultrasonic treatment has a promoting effect on the dye release 295 
from the microcapsules with the gold nanoparticles. After the fourth (total 60 minutes) ultrasonic 296 
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treatment, the dye was still released from the samples. However, the rate of the Rhodamine 6G 297 
concentration changes was reduced, particularly for the medium and low-duty cycle treatments. After the 298 
sixth ultrasonic stimulation (90 minutes), the Rhodamine 6G concentration of the dye released from the 299 
sample under the high-duty cycle treatment was close to the initial total intensity of the dye adsorbed 300 
onto the microcapsules. This implies that most of the dye contained in the samples had been released. In 301 
comparison, the Rhodamine 6G released from the samples with the medium or low-duty cycle of 302 
ultrasound was lower than with the high-duty cycle. This means that there was still some dye in the 303 
microcapsules. This is not surprising as the medium or low-duty cycle of ultrasound presented lower 304 
power intensities than the high-duty cycle of ultrasound, causing a lower dye to be released from the 305 
microcapsules. Nevertheless, the dye released from the microcapsules with ultrasonic stimulation was 306 
still presented.  307 
 308 
To study the influence of gold nanoparticles on the efficiency of the dye release, microcapsules without 309 
gold nanoparticles in their shells were also synthesized and analyzed. Their results are shown in Figure 7. 310 
The graph represents means with error bars for six times. Graph markers denote the data mean. The bars 311 
indicate data range. 312 
 313 
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 314 
Figure 7. Rhodamine 6G concentration of the dye released from the capsules without gold nanoparticles measured after 315 
various ultrasonic stimulation times of different duty-cycles. 316 
 317 
It shows that there is no obvious changes in the concentration and R6G concentration is below 3% of the 318 
total concentration after six cycles of stimulation.  However, the change of fluorescence intensity with 319 
the increase of the ultrasonic stimulation time was small. After the 6th stimulation, the concentration of 320 
Rh6G was just 10% of the total initial concentration of Rh6G. Moreover, there was no significant 321 
difference in the efficiency of the dye released by employing different duty cycles. It is thus clear that 322 
gold nanoparticles in microcapsules play an important role in the ultrasonic induced release of dye.  323 
 324 
Finally, the release of dye from samples (1.5 ml) stored at room temperature at 200 without ultrasonic 325 
treatment during a period of four weeks was also studied as a comparison. Both microcapsules with and 326 
without gold nanoparticles were used in this study. Figure 8 shows the Rhodamine 6G concentration 327 
changes of the dye released from microcapsules after a long period of storage at room temperature at 20 328 
degrees. 329 
 330 
(a) 331 
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 332 
(b) 333 
Figure 8.  Rhodamine 6G concentration of dye released from capsules (a) with and (b) without gold nanoparticles after room 334 
temperature storage (without any ultrasonic stimulation). The red line represents the Rhodamine 6G contained in the samples. 335 
 336 
Figure 8 (a) shows that after an initial small release in the first week, a large amount of dye was released 337 
from microcapsules with gold nanoparticles in the following three weeks. The graph represents means 338 
with error bars for five times. Graph markers denotes the data mean. The bars indicate data range. In 339 
contrast, no obvious changes in the Rhodamine 6G concentration was observed in the case of 340 
microcapsules without gold nanoparticles for the first few weeks. The intensity of released dye after 4 341 
weeks was significantly weak compared to that from microcapsules with gold nanoparticles. This finding 342 
suggests that microcapsules containing gold nanoparticles are less stable compared to those without gold 343 
nanoparticles. 344 
 345 
 346 
4. Discussion 347 
In this study, the presence of gold nanoparticles allowed the dye to be released from PLA-348 
Rh6G/PAH/PSS/PAH/AuNP/PAH microcapsules more efficiently, compared to microcapsules without 349 
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gold nanoparticles. According to these results, several factors may play a role in the stimulation process. 350 
The presence of gold nanoparticles in the microcapsules makes the shells stiffer and lower in their 351 
elasticity, which may have an effect on how easily the shells will move when applying  an oscillating 352 
force to them in liquid by means of ultrasonic stimulation. If they are moved, the rupturing may occur as 353 
expected. As illustrated by Fery et al., the presence of inorganic nanoparticles increases the density 354 
contrast of a microcapsule shell, which also decreases the elasticity of the shell. These are important for  355 
achieving high efficiency in  the ultrasonically treated release of compounds encapsulated in capsules 356 
[39].  357 
 358 
The effects of ultrasound as a release trigger may be attributed to acoustic cavitation in liquids under 359 
ultrasonic vibrations with a frequency of more than 20 kHz. As demonstrated by Maria N. Antipina et al., 360 
ultrasound energy produces pressure and can cause the shrinkage of gas-filled nanobubbles. Then, the 361 
cavitating nanobubbles implode, which produces local shock waves and destroy the nanocapsules 362 
assemblies [40-44]. Even at low input power, the collapse of microbubbles in liquid results in an 363 
enormous concentration of energy. When the capsules are subjected to ultrasonic stimulation, shear 364 
forces between the successive fluid layers occurs, which leads to the disruption of the capsule assemblies 365 
and the subsequent release of their payloads [39]. Therefore, acoustic cavitation resulted in dye release 366 
from the nanocapsules in this study is a possible factor. 367 
 368 
As for the nanocapsules without gold nanoparticles, they presented little dye release in this research. It 369 
can be assumed that the capsules may be disrupted because of the absorption of intense energy of 370 
ultrasound over a longer time. In previous research by academics, ultrasonic stimulation operating on the 371 
capsules has been proven to produce heat. High temperature causes changes in permeability of the outer 372 
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shell and can even rupture the capsules. Subsequently, the release of capsules payload will be achieved 373 
[45]. The heat produced by ultrasound may also have an influence on the dye released from samples 374 
without gold nanoparticles.  375 
 376 
5. Conclusions 377 
This work aims to investigate a drug delivery system with stimuli-responsive polymeric microcapsules 378 
that can achieve a locally controlled drug release by means of remote ultrasonic stimulation. The 379 
microcapsules were synthesized with polyelectrolyte layers and gold nanoparticles by means of a layer-380 
by-layer assembly technique, encapsulated with a model dye used in place of anti-restenotic drugs. The 381 
microcapsules with and without gold nanoparticles embedded in the shell were examined for their 382 
response to ultrasonic stimulation. The presence of gold nanoparticles significantly enhances the 383 
efficiency of the ultrasonically induced dye release from the microcapsules. It is shown that the 384 
microcapsules containing gold nanoparticles are more sensitive to ultrasonic treatment compared with the 385 
microcapsules without gold nanoparticles. Such a method will give the interventional cardiologist more 386 
control over the medical implants. 387 
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